

Sherbet Fountains and Inhaler Devices – What do they have in common ?



(Getting the most from inhaler devices)

Thursday 10th April 2008

Jon Bell


Canday Medical Limited

Who ?

Pharmaceutical companies – sales & marketing, then clinical research

Medical device company – peak flow, spirometry, inspiratory (In-Check)

Present – independent research
“inspiratory” – measurement & training
(Asthmatic; triggers - cat dander + lime cordial)



Aims / Goal ?

1. Promote improved care through better understanding of basic aerosol science and device characteristics
2. Minimise waste with inhaled drug therapies
3. Increase respiratory MURs through application of knowledge of how devices work, and how to achieve optimum technique – no matter what device patient has.



Asthma and Pets



The screenshot shows the Allerca website with a navigation menu at the top: HOME, CAT ALLERGIES, HYPO-ALLERGENIC CATS, DEVELOPMENT, BUY A KITTEN, ABOUT ALLERCA, CONTACT. The main header features the Allerca logo and a "SUBSCRIBE TO OUR NEWSLETTER" button. Below the header, a text block states: "ALLERCA has produced the world's first scientifically-proven hypoallergenic cats. These cats allow some of the millions of people with feline allergies to finally enjoy the love and companionship of a household pet without suffering from allergic symptoms." To the right of this text is a photo of a tabby cat sitting upright and a "CUSTOMER LOGIN" link.

CAT ALLERGIES [LEARN MORE](#)

Currently most treatments for cat allergies focus on avoidance, allergy shots, and pharmaceuticals. This section provides more information on how until the advent of the ALLERCA cats, the choice has been either to live without a pet or make considerable alterations in one's living environment.

HYPO-ALLERGENIC CATS [LEARN MORE](#)

ALLERCA has produced the world's first scientifically-proven hypoallergenic cats. This section provides more information on why an ALLERCA cat is the ideal companion for people with feline allergies. Please also take our quick survey and help us decide future breeds of hypoallergenic cats.

DEVELOPMENT [LEARN MORE](#)

The ALLERCA research and development team has placed ALLERCA in a unique position to...

As featured on CBS Early Show
click on the PLAY button to view

Medications for Asthma Management

- “Reliever” Meds
- Taken as needed
- To relieve acute airflow obstruction and bronchoconstriction
- Primarily **Beta₂-Agonists**

“Blue” inhaler

- “Preventer” Meds
- Taken daily, long-term
- To reduce inflammation
 - Primarily **inhaled corticosteroids**


“Brown” inhaler

- Combination products

“Purple” or “Red/White” inhaler

The importance of explaining asthma medications

Relievers



Preventers





Consequence of poor compliance



Increased use of
relievers



...and reduced protective effect



Could we do
something similar to
explain COPD
medications ?

Asthma UK estimates that 2.1 million patients in the UK are suffering unnecessarily because they do not use their asthma treatment effectively.

An estimated 75% of hospital admissions for asthma are avoidable and as many as 90% of the deaths from asthma are preventable.




http://www.asthma.org.uk/news_media/media_resources/for_1.html

Last accessed: 3rd October 2007



UK: MDI and DPI Inhalation technique: inhalation too fast for pMDI, or too slow for DPI



Guideline recommendations (NICE COPD 2004)

Issue date: February 2004

Quick reference guide



National Institute for
Clinical Excellence

Chronic obstructive pulmonary disease

Management of chronic obstructive
pulmonary disease in adults in primary and
secondary care

Delivery systems

Inhalers

- Most patients, whatever their age, can learn how to use an inhaler unless they have significant cognitive impairment.
- Hand-held devices are usually best, with a spacer if appropriate. **D**
- If a patient cannot use a particular device, try another. **D**
- Teach technique before prescribing an inhaler, and check regularly. **D**
- Titrate the dose against response for each patient. **D**

...but what if the half the dose is wasted
each time the inhaler is used

“How do you inhale” challenge

Quick test of how you would inhale through commonly-used devices


- pMDI measurement first
- DPI measurement second

Need to:

1. Simulate resistance of device
2. Measure speed of inhalation

“How you would instruct the patient to inhale” using that type of inhaler


Single measurement



Results later

Mean resistance of various DPIs

Resistance in $(\text{cmH}_2\text{O})^{1/2}\text{Lmin}^{-1}$



Assi KH, Chrystyn H. The different resistance of dry powder inhalers (DPIs).
Am. J Respir. Crit. Care Med. 2001;163(5): A443 (Adapted from)

Health Professionals speed of inhalation when asked to inhale as if using an MDI - "Slowly and Deeply"

Speed of inhalation

60 L/min or less

(n=179)

61 to 90 L/min

(n=267)

91 L/min and above

(n=2825)

Metered Dose Inhaler (MDI)



Total = 3271 tests conducted :
over **94%** inhaled too fast

General Practitioners, Practice Nurses, Respiratory Nurses (Primary & Secondary Care), Pharmacists (Community, Retail and Hospital), Pharmacy Dispensers, Prescribing Advisors, Physiotherapists, Hospital Physicians (General Medicine and Thoracic), Pharmaceutical Company Employees (Representatives, Medical Advisors, Educational Staff)

Presented at ERS Annual Scientific Meeting, Stockholm 2007 (No. 91, Primary Care Day, 15/9/07):
Jon Bell, Canday Medical Ltd. data collected between 1st June 2006 and 5th September 2007

Asthmatics - speed of inhalation through Metered Dose Inhaler

Speed of inhalation

Metered Dose Inhaler (MDI)



90 L/min or less


(n=36)

Total = 476 individuals tested :
over **92%** inhaled too fast


91 L/min and above

(n=440)

Fate of inhaled drugs – Good Technique



Fate of inhaled drugs – **Poor** Technique



Why are there problems ?



- Design of inhalers vary


- Formulation of drug
- Mechanical activation
(passive MDI vs active DPI)
- Internal resistance to airflow

*inappropriate
selection
and/or
incorrect
inhaler
technique*


- Patients vary

- Pulmonary function
(reversible Vs irreversible disease)
- Ability to learn / be taught the correct technique
- Physical size of lungs (child vs adult)
- Effort varies from dose to dose

External shape hides internal differences




High resistance



Low resistance

Flow / Resistance Profiles



Resistance of 3 Common Inhalers at different flow rates


(placebo versions)

Dry powder device



pMDI aerosol "puffer"

—◆— AstraZeneca's Turbohaler
—▲— 3Ms HFA pMDI
—■— GlaxoSmithKline's Accuhaler

Changes in inspiratory flow affect the aerosol output from two types of portable inhaler



Aerosol Deposition at varying Particle Size



Facio-Maxillary View (lateral)



Right Bronchogram



n.b. note the angles of the airways

Particle Deposition In Respiratory Tract

Three mechanisms of aerosol kinetics govern the majority of particle deposition within the respiratory tract.

1. Inertial impaction
90%



Mass



Speed

2. Sedimentation
9%



Gravity

3. Diffusion
1%



Brownian motion*

* Whitley Bay Smoke Chamber

What have sherbet fountains got in common with inhalers



Twisthaler



pMDI



Turbohaler



Handihaler




Accuhaler

Implications

Metered Dose Inhalers

Lung deposition from pMDIs is influenced by inspiratory flow



Metered Dose Inhaler (MDI)



Implications


Spacer Devices

Spacer Devices – How they help



Metered Dose Inhaler (MDI)

Drug



1. Capture aerosol avoiding coordination problems
2. Reduces large aerosol particles (associated with s/e)

Errors in Technique

No. 129


Asthma patient audit : 1 patient, Male 55yr
28 salbutamol MDI Rx in last 12 months
2000 mcg BDP
Poor inhaler technique
L. Vol. Spacer repeatedly prescribed



Implications

Dry Powder Devices

Lung deposition from Turbohaler is influenced by inspiratory flow




Lung deposition from a budesonide Turbohaler measured by gamma scintigraphy.

Dry Powder Inhaler (DPI)



Total emitted dose at different flow rates




Application of PIF Measurement

Application of existing flow measurement technology



Measures speed of exhalation PEF (l/min)


- Diagnosis for reversible airway disease
- Monitor response to treatment
- Identify provocative factors
- Objective input for self-management



Measures speed of inhalation PIF (l/min)

- Measure inspiratory flow for inhaler used
- Identify poor inhalation technique
- Demonstrate optimal technique for inhaler
- Objective feedback on teaching success
- (with facemask) monitors allergic rhinitis morbidity (Peak NASAL inspiratory flow – PNIF)

1. Turn the DIAL to select the inhaler resistance



(Diskus / Accuhaler)
Multiple-dose powder inhaler




(Common pMDI)
Metered Dose Inhaler and MDI spacers with low resistance (e.g. AbleSpacer)



(Easibreathe)
Automatic pMDI












(Turbuhaler)
Turbulent flow inhaler



(Autohaler)
Automatic pMDI





2. Measure, then compare the inspiratory flow achieved with the optimum recommended for that device

		Optimum Inspiratory Flow Range (l/min)										
		10	20	30	40	50	60	70	80	90	100	110
Multiple-dose powder inhaler Accuhaler												
Turbulent flow inhaler (old style) Turbuhaler®												
Turbulent flow inhaler (Symbicort®) Turbuhaler®												
Auto inhaler Autohaler®												
Auto inhaler Easi-Breathe®												
Multiple-dose powder inhaler Clickhaler®												
Low-resistance aerosol pMDI	 or 											

“Optimum”
Or
“Effective”

?

Is there a difference between “effective” and “optimum” ?



VS.

1. Clinical effect observed

1. Lung deposition is maximised
2. Oropharyngeal deposition is minimised
3. Clinical benefit is maximised
4. Side-effect risk is minimised
5. Inhaler provides greater dose consistency

The optimum inspiratory flow range for each device has been ascertained after reference to pharmaceutical data - summary of product characteristics (SPC), promotional and educational literature (from the manufacturers) and clinical and laboratory studies.

What if asthma and COPD were treated with Chocolates and Champagne ?



£5 to £20 a box



£15 to £35 a bottle

Would you allow people to waste 50% every time they had some ?

Assessment & Training Devices

Monitoring inspiratory flow rate through the device

Independent



Vitalograph's
Aerosol Inhalation
Monitor (AIM)



Clement Clarke's In-Check
and In-Check DIAL



Fyne Dynamic's
MagFlo



Canday
Medical's
"2-Tone" Trainer

(www.2ToneTrainer.com)

Pharmaceutical Co.



60 L/min



35 L/min



AstraZeneca's
Turbohaler Usage
Trainer &
Turbutesters

Schering-Plough's
Twisthaler Trainer



Inhale Too Fast.... (e.g. pMDI)



High-speed aerosol cloud impacts in oropharynx

Inhale Too Slowly.... (e.g. DPI)



Reduced emitted dose and quality of aerosol at
low speed

Inhale Optimally (e.g. pMDI)



Optimal PIF for inhaler efficiency and
aerosol dynamics

Points to take away ?

1. Internal **resistance** affects speed of inhalation
2. Speed of inhalation affects **DPI device efficacy** (less effect on MDI)
3. Speed of inhalation affects how much drug is **deposited** in the lungs – and how much in the mouth and throat
4. Teaching **optimum technique** (rather than just any technique that shows clinical effect) offers real and immediate benefits for both patient and professional.